7/17/17 9:45PM--looks like a perfect head-and-shoulder pattern forming since early-June, with the SP trading in a tight range the last few sessions. Is this a good point to get in? What are some near term catalysts?
how does this hold $15.10 when shares are being offered at $14.50?
In the short-term AKBA does not seem to be like a good trade. check out awesom-eSTOCKS, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
AKBA vs FGEN
40 mil shares outstanding vs 70 million
300 plus mil cash vs 130 mil minus debt.
strong partners vs 8 month lead in HIF program
550 million market cap vs 1.9 billion
HIF only vs HIF and Fibrosis
you decide which one is better !!
It will fill the gap until there is news. $13 was the last high before it popped last week. Buy more or sell now and buy later.
See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio.
• BioLargo’s 10Q states their Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days • Woundcare market is over $6 Billion with high growth rate • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost • Sales could commence in first half of 2018 • Sales and or licensing agreement/s could be very significant • Company is now commercializing several other disruptive products in large markets
Harry Boxer has posted his Charts of the Day video on AKBA at TheTechTrader site noting: Akebia Therapeutics, Inc. (AKBA) had a big day on Tuesday, popping 2.11, or 16%, to 15.01, on 6.6 million shares traded. It popped up, pulled back, popped again, but couldn’t get through the high, and drifted down the rest of the day. It might swing toward 18. That’s my swing target. If it holds 14.68-.70 on Wenesday, and starts to move up again, it could accelerate to 17, 18, even 19.
$50 MILLION reasons to stay long ... $14 is the base for this stock. $20 short term is conservative.
The fresenius contract is a Big move.
great bounce just below 15.... should close over 16?
This news can have some serious legs over the weekend huge contract win
Anyone has opinion on why the stock took such a big dip today?
Harry Boxer has posted his Charts of the Day video on AKBA at TheTechTrader site noting: Akebia Therpeutics, Inc. (AKBA) had a beautiful inside day on Thursday, following the explosive move it had on Wednesday, still gaining 73 cents, or 6%, to 13.23, on 4.8 million shares traded. Volume reduced but still very strong. Overall, it was a positive inside day. Watch to see if it gets over 14. If so, targets are 15, 16, even 18 going forward.
I like the product, I like the company, I like the leadership - going to keep holding.
Anyone else riding this one?
hold on tight this should be worth 800 million
Is it possible that many people that are tethered to portable oxygen tanks, and generators could get rid of them if they could use Vadadustat instead?
Does anything think if AKBA is gonna have good run again tomorrow?